Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on LinkedIn:
“A new era in regenerative medicine begins.
The first patient has been treated in a first-in-human clinical trial evaluating partial cellular reprogramming for glaucoma-a milestone in the quest to restore function to aging tissues.
Researchers are activating three reprogramming genes (excluding the oncogenic c-MYC factor) to rejuvenate retinal ganglion cells and promote regeneration of the optic nerve, a tissue traditionally considered incapable of meaningful repair. Gene expression is controlled with doxycycline, providing an added layer of safety by allowing investigators to switch the therapy on and off.
The approach builds on compelling preclinical studies showing reversal of vision loss and optic nerve regeneration in aged animal models. However, important questions remain regarding long-term safety, durability, and the potential risk of tumor formation.
While this study targets glaucoma rather than aging itself, it represents one of the first clinical tests of partial cellular reprogramming in humans-and could mark an important step toward regenerative therapies for age-related diseases.
The future of medicine may involve not only slowing disease progression, but restoring the biology of aging tissues.”
Other articles featuring Yan Leyfman on OncoDaily.